» Articles » PMID: 16157527

18F-FDG PET for Staging Breast Cancer in Patients with Inner-quadrant Versus Outer-quadrant Tumors: Comparison with Long-term Clinical Outcome

Overview
Journal J Nucl Med
Specialty Nuclear Medicine
Date 2005 Sep 15
PMID 16157527
Citations 8
Authors
Affiliations
Soon will be listed here.
Abstract

Unlabelled: Extraaxillary metastases (i.e., in the absence of axillary involvement) are more likely to develop in patients with inner-quadrant (IQ) breast cancer than in patients with outer-quadrant (OQ) primary tumors. The relative difficulty of identifying extraaxillary metastases may lead to understaging of cancer in these patients. This study examined whether (18)F-FDG PET findings were differentially associated with the location of primary tumors, and with long-term prognosis, in IQ and OQ patients.

Methods: Follow-up data were obtained for 141 patients whose breast cancer was staged by PET and who were documented to have IQ (n = 42) or OQ (n = 99) primaries. Results were stratified according to PET findings consistent with different metastatic patterns. Data were further analyzed with respect to disease outcome after a mean 3-y follow-up period.

Results: Among IQ patients, progressive disease was identified in 26.1%, compared with 13.1% of OQ patients, for a relative risk (RR) of 2.0. Of patients with PET findings of isolated extraaxillary metastases, 36.1% had progressive disease, compared with 10.7% of other patients (RR = 3.4), and 61.9% of IQ patients had isolated extraaxillary metastases identified on PET, compared with 10.1% of OQ patients (RR = 6.1).

Conclusion: IQ patients demonstrated a 6-fold greater frequency of PET findings of isolated extraaxillary metastasis, and such findings were associated with triple the risk for disease progression. Patients with IQ tumors could be vulnerable to understaging with conventional staging approaches and may particularly benefit from PET during the staging process.

Citing Articles

Clinical characteristics of breast cancer patients admitted to academic surgical wards in Tehran, Iran: an analytical cross-sectional study.

Pourriahi R, Omranipour R, Alipour S, Hajimaghsoudi L, Mashoori N, Kenary A BMC Womens Health. 2023; 23(1):511.

PMID: 37743485 PMC: 10518944. DOI: 10.1186/s12905-023-02637-0.


The use of 18F-FDG positron emission tomography to detect mediastinal lymph nodes in metastatic breast cancer.

Onal C, Findikcioglu A, Guler O, Reyhan M Breast. 2020; 54:197-202.

PMID: 33125983 PMC: 7593617. DOI: 10.1016/j.breast.2020.10.011.


Modulation of glucose transporter 1 (GLUT1) expression levels alters mouse mammary tumor cell growth in vitro and in vivo.

Young C, Lewis A, Rudolph M, Ruehle M, Jackman M, Yun U PLoS One. 2011; 6(8):e23205.

PMID: 21826239 PMC: 3149640. DOI: 10.1371/journal.pone.0023205.


International expert panel on inflammatory breast cancer: consensus statement for standardized diagnosis and treatment.

Dawood S, Merajver S, Viens P, Vermeulen P, Swain S, Buchholz T Ann Oncol. 2010; 22(3):515-523.

PMID: 20603440 PMC: 3105293. DOI: 10.1093/annonc/mdq345.


Disease Restaging and Diagnosis of Recurrent and Metastatic Disease Following Primary Therapy with FDG-PET Imaging.

Eubank W, Lee J, Mankoff D PET Clin. 2010; 4(3):299-312.

PMID: 20161481 PMC: 2794199. DOI: 10.1016/j.cpet.2009.09.001.